MIR302F

Summary

MIR302F (microRNA 302f, HGNC:35349) is a microRNA gene on chromosome 18q12.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100302131 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:35349
Approved symbol	MIR302F
Name	microRNA 302f
Location	18q12.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-302f
Ensembl gene	ENSG00000283218
Ensembl biotype	miRNA
Entrez	100302131
RNAcentral	URS000075C007 — miRNA, 51 nt, 2 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000635955

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000635955 — 1 exons

Exon	Start	End
ENSE00003795824	30298910	30298960

Expression profiles

Bgee: expression breadth broad, 13 present calls, max score 75.43.

Top tissues by expression

13 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	75.43	gold quality
esophagus mucosa	UBERON:0002469	70.31	gold quality
lower esophagus muscularis layer	UBERON:0035833	69.78	gold quality
transverse colon	UBERON:0001157	68.56	gold quality
subcutaneous adipose tissue	UBERON:0002190	68.55	gold quality
right frontal lobe	UBERON:0002810	67.99	gold quality
skin of leg	UBERON:0001511	67.04	gold quality
spleen	UBERON:0002106	65.98	gold quality
prostate gland	UBERON:0002367	65.31	gold quality
vagina	UBERON:0000996	64.44	gold quality
endocervix	UBERON:0000458	62.92	gold quality
left ovary	UBERON:0002119	62.26	gold quality
left testis	UBERON:0004533	50.32	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.33

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 2)

• FGF12, RBFOX1, and MIR302F could be important in human heterotaxy, because they were noted in multiple cases. Further investigation into genes involved in the NODAL, BMP, and WNT body patterning pathways and into the dosage effects of FGF12, RBFOX1, and MIR302F is warranted. (PMID:27637763)
• The present study revealed three gout specific loci, CNTN5, MIR302F, ZNF724, to be clearly associated with mechanisms of gout development, which distinctly differ from the known gout risk loci that basically elevate serum uric acid level. This meta-analysis is the first to reveal the loci associated with crystal-induced inflammation, the last step in gout development that aggravates asymptomatic hyperuricaemia into gout. (PMID:31289104)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.